INIS
radiotherapy
100%
cancer
71%
tumors
68%
immunotherapy
63%
patients
62%
lung cells
42%
therapy
29%
doses
28%
lungs
25%
antibodies
24%
immunity
21%
lymphocytes
21%
clinical trials
20%
humans
20%
accelerators
20%
toxicity
20%
fluorine 18
20%
decision making
20%
brakes
20%
charged particles
20%
biological markers
20%
hypoxia
20%
positron computed tomography
20%
interleukins
20%
organs
20%
radiomics
20%
metastases
18%
reviews
18%
blood vessels
16%
lymphopenia
16%
Keyphrases
Radiotherapy
60%
L19-IL2
60%
Interleukin-2
24%
Tumor
23%
Tumor Immunity
22%
Phase II Trial
22%
Stereotactic Body Radiation Therapy
22%
Fibronectin
22%
Non-small Cell Lung Cancer (NSCLC)
22%
Standard of Care
20%
In Cancer
20%
Web-based
20%
Phase 1 Study
20%
Non-small Cell Lung Cancer Patients
20%
Stereotactic Ablative Radiotherapy
20%
Targeted Therapy
20%
Patient Decision Aid
20%
Shared Decision Making
20%
Hypoxia
20%
Immunogenic Tumor
20%
Quantitative Imaging
20%
Anti-PD-1
20%
Lymphocytes
20%
Extra Domain B
20%
Conventional Radiotherapy
20%
18F-HX4
20%
Lung Cancer Treatment
20%
Radiomics
20%
Positron Emission Tomography
20%
Particle Radiotherapy
20%
Medicine and Dentistry
Radiation Therapy
60%
Immunotherapy
44%
Non Small Cell Lung Cancer
40%
Darleukin
40%
Neoplasm
26%
Cancer Therapy
24%
Quantitative Imaging
20%
Lung Cancer
20%
Phase II Trials
20%
Hypoxia
20%
Fluorine-18
20%
Tumor Immunity
20%
Shared Decision Making
20%
Radiomics
20%
Positron Emission Tomography
20%
Radioactive Tracer
20%
Programmed Death-Ligand 1
20%
Lymphocyte
20%
Lymphocytopenia
16%
Metastatic Carcinoma
10%
Multiple Choice Test
10%
Likert Scale
10%
Tumor Hypoxia
8%
Clinical Trial
6%
Survival Rate
6%
Progression Free Survival
6%
Immune Checkpoint Inhibitor
6%
Chemotherapy
6%
Lewis Lung Carcinoma
6%
Immunity
6%
